8VC and Mubadala Capital led a $42m series D funding round in Alloy Therapeutics.

8VC, a technology and life sciences investment firm, and Mubadala Capital, a capital market company, led a $42m series D funding round in Alloy Therapeutics, a biotechnology ecosystem company, with participation from Thiel Capital, Presight Capital and Founders Fund. “Alloy has successfully expanded its flagship discovery offering in antibodies to multiple promising modalities to better serve the global drug discovery community. We are proud to partner with the company as it executes on its promise of enabling scientists through the development of transformative drug discovery technologies. We look forward to seeing how the partnership with large pharma partners and other venture firms will leverage Alloy’s platform to enable their therapeutic discovery teams and emerging startups to advance the best medicines,” Alaa Halawa, Mubadala Capital Head of US Ventures business.